Regadenoson
- Generic Name
- Regadenoson
- Brand Names
- Lexiscan, Rapiscan
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N8O5
- CAS Number
- 313348-27-5
- Unique Ingredient Identifier
- 7AXV542LZ4
- Background
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
- Indication
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Drug: RegadenosonProcedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1147
- Registration Number
- NCT01618669
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Mobile Heart Specialists, PC, Mobile, Alabama, United States
🇺🇸HOCC - New Britain Campus, New Britain, Connecticut, United States
Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Dipan Shah
- Target Recruit Count
- 50
- Registration Number
- NCT01446094
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers
- Conditions
- Heart Disease
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 70
- Registration Number
- NCT01433705
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT01370265
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Drug: regadenosonRadiation: technetium Tc99m sestamibi /technetium Tc99m tetrafosminRadiation: ContrastProcedure: Single Photon Emission Computed TomographyProcedure: Multidetector Computed Tomography
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT01334918
- Locations
- 🇺🇸
Cardiovascular Research Center of South Florida, Miami, Florida, United States
🇺🇸Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Harbor UCLA Medical Center, Torrance, California, United States
Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 46
- Registration Number
- NCT01161121
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
🇺🇸St. Louis University, Saint Louis, Missouri, United States
Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 39
- Registration Number
- NCT01085201
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 40
- Registration Number
- NCT01026012
- Locations
- 🇺🇸
University of MD Cardiology Physicians, Westminster, Maryland, United States
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
- Conditions
- Coronary Artery DiseaseMyocardial Ischemia
- Interventions
- Other: Symptom-limited exerciseDrug: Regadenoson
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT01021618
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
- Conditions
- Coronary Artery DiseaseType 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 26
- Registration Number
- NCT01019486
- Locations
- 🇺🇸
Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
🇺🇸University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.